A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors

被引：0
|
作者：
Shigehisa Kitano
Yutaka Fujiwara
Toshio Shimizu
Satoru Iwasa
Kan Yonemori
Shunsuke Kondo
Akihiko Shimomura
Takafumi Koyama
Takahiro Ebata
Hiroki Ikezawa
Nozomi Hayata
Yukinori Minoshima
Takuma Miura
Tomoki Kubota
Noboru Yamamoto
机构：
[1] National Cancer Center Hospital,Department of Experimental Therapeutics
[2] The Cancer Institute Hospital of JFCR,Department of Advanced Medical Development
[3] Aichi Cancer Center,Department of Thoracic Oncology
[4] National Center for Global Health and Medicine,Department of Breast and Medical Oncology
[5] Eisai Co.,Clinical Data Science Department
[6] Ltd,Clinical Pharmacology Science Department
[7] Eisai Co.,Japan and Asia Clinical Development Department
[8] Ltd,undefined
[9] Tsukuba Research Laboratories,undefined
[10] Eisai Co.,undefined
[11] Ltd,undefined
[12] Eisai Co.,undefined
[13] Ltd,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 90卷
关键词：
Biomarkers; Lenvatinib; Pembrolizumab; Pharmacokinetics; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：523 / 529
页数：6
相关论文
共 50 条
  • [1] A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
    Kitano, Shigehisa
    Fujiwara, Yutaka
    Shimizu, Toshio
    Iwasa, Satoru
    Yonemori, Kan
    Kondo, Shunsuke
    Shimomura, Akihiko
    Koyama, Takafumi
    Ebata, Takahiro
    Ikezawa, Hiroki
    Hayata, Nozomi
    Minoshima, Yukinori
    Miura, Takuma
    Kubota, Tomoki
    Yamamoto, Noboru
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (06) : 523 - 529
  • [2] The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors
    Taylor, Matthew H.
    Schmidt, Emmett, V
    Dutcus, Corina
    Pinheiro, Elaine M.
    Funahashi, Yasuhiro
    Lubiniecki, Gregory
    Rasco, Drew
    [J]. FUTURE ONCOLOGY, 2021, 17 (06) : 637 - 647
  • [3] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael Sangmin
    Wolf, Ido
    Fakih, Marwan
    De Vos-Geelen, Judith De
    Lee, Valerie
    Vogel, Arndt
    Wu, Larry
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael S.
    Wolf, Ido
    Fakih, Marwan
    de Vos-Geelen, Judith
    Lee, Valerie
    Vogel, Arndt
    Wu, Xi Lawrence
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Movva, Sujana
    Avutu, Viswatej
    Chi, Ping
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Kelly, Ciara Marie
    Keohan, Mary Louise
    Meyers, Paul A.
    Cohen, Seth M.
    Hensley, Martee Leigh
    Konner, Jason A.
    Schram, Alison M.
    Lefkowitz, Robert A.
    Erinjeri, Joseph Patrick
    Qin, Li-Xuan
    Salcito, Tiffany
    Seier, Kenneth
    Tap, William D.
    D'Angelo, Sandra P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Movva, Sujana
    Avutu, Viswatej
    Chi, Ping
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Kelly, Ciara Marie
    Keohan, Mary Louise
    Nacev, Benjamin Alexander
    Rosenbaum, Evan
    Thornton, Katherine Anne
    Cohen, Seth M.
    Hensley, Martee Leigh
    Konner, Jason A.
    Schram, Alison M.
    Qin, Li-Xuan
    Lefkowitz, Robert A.
    Erinjeri, Joseph Patrick
    D'Angelo, Sandra P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] An open-label phase 1 trial of lenvatinib plus pembrolizumab in patients with advanced selected solid tumors
    Kitano, Shigehisa
    Fujiwara, Yutaka
    Shimizu, Toshio
    Iwasa, Satoru
    Yonemori, Kan
    Kondo, Shunsuke
    Shimomura, Akihiko
    Koyama, Takafumi
    Ebata, Takahiro
    Iizumi, Sakura
    Ikezawa, Hiroki
    Namiki, Masayuki
    Kubota, Tomoki
    Miura, Takuma
    Yamamoto, Noboru
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [8] Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Cohn, Allen L.
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    DiSimone, Christopher
    Messing, Mark
    Stepan, Daniel E.
    Dutcus, Corina E.
    Wu, Jane
    Schmidt, Emmett V.
    Orlowski, Robert
    Sachdev, Pallavi
    Shumaker, Robert
    Casado Herraez, Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) : 2981 - 2992
  • [9] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
    Eto, Masatoshi
    Takagi, Toshio
    Kimura, Go
    Fukasawa, Satoshi
    Tamada, Satoshi
    Miura, Yuji
    Oya, Mototsugu
    Sassa, Naoto
    Anai, Satoshi
    Nozawa, Masahiro
    Sakai, Hideki
    Perini, Rodolfo
    Yusa, Wataru
    Ikezawa, Hiroki
    Narita, Tomoyuki
    Tomita, Yoshihiko
    [J]. CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
  • [10] Phase 2 study of lenvatinib plus pembrolizumab in previously treated patients with solid tumors: LEAP-005
    Geva, Ravit
    Im, Seock-Ah
    Lwin, Zarnie
    Weil, Susan
    Xu, Lei
    Morosky, Anne
    Norwood, Kevin
    Chung, Hyun Cheol
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345